Home/Filings/4/0000899243-22-036695
4//SEC Filing

Giffin Brett A. 4

Accession 0000899243-22-036695

CIK 0001492674other

Filed

Nov 21, 7:00 PM ET

Accepted

Nov 22, 4:00 PM ET

Size

8.9 KB

Accession

0000899243-22-036695

Insider Transaction Report

Form 4
Period: 2022-11-08
Giffin Brett A.
Chief Commercial Officer
Transactions
  • Sale

    Common Stock

    2022-11-10$1.79/sh1,292$2,3172,253 total
  • Exercise/Conversion

    Common Stock

    2022-11-08+3,3333,545 total
  • Exercise/Conversion

    Restricted Stock Units

    2022-11-083,3336,667 total
    Common Stock (3,333 underlying)
Footnotes (3)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
  • [F2]The sale reported in this Form 4 was made in order to pay the tax liability arising from vesting and settlement of RSU's on November 8, 2022. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the reporting person.
  • [F3]On February 26, 2022 the reporting person was granted 10,000 RSU's that vest in three substantially equal installments on November 8, 2022, November 8, 2023, and October 1, 2024.

Issuer

T2 Biosystems, Inc.

CIK 0001492674

Entity typeother

Related Parties

1
  • filerCIK 0001892921

Filing Metadata

Form type
4
Filed
Nov 21, 7:00 PM ET
Accepted
Nov 22, 4:00 PM ET
Size
8.9 KB